- Home
- VALE vs ARGX Comparison
VALE vs ARGX Comparison
Compare VALE & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VALE
- ARGX
- Stock Information
- Founded
- VALE 1942
- ARGX 2008
- Country
- VALE Brazil
- ARGX Netherlands
- Employees
- VALE N/A
- ARGX N/A
- Industry
- VALE Metal Mining
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VALE Basic Materials
- ARGX Health Care
- Exchange
- VALE Nasdaq
- ARGX Nasdaq
- Market Cap
- VALE 38.4B
- ARGX 40.4B
- IPO Year
- VALE N/A
- ARGX 2017
- Fundamental
- Price
- VALE $9.37
- ARGX $549.65
- Analyst Decision
- VALE Buy
- ARGX Strong Buy
- Analyst Count
- VALE 9
- ARGX 20
- Target Price
- VALE $12.66
- ARGX $698.22
- AVG Volume (30 Days)
- VALE 26.1M
- ARGX 423.4K
- Earning Date
- VALE 04-24-2025
- ARGX 05-08-2025
- Dividend Yield
- VALE 8.86%
- ARGX N/A
- EPS Growth
- VALE N/A
- ARGX N/A
- EPS
- VALE 1.23
- ARGX 15.94
- Revenue
- VALE $35,590,156,070.00
- ARGX $2,643,062,000.00
- Revenue This Year
- VALE N/A
- ARGX $60.97
- Revenue Next Year
- VALE $3.20
- ARGX $31.50
- P/E Ratio
- VALE $7.64
- ARGX $32.07
- Revenue Growth
- VALE N/A
- ARGX 82.13
- 52 Week Low
- VALE $8.06
- ARGX $352.77
- 52 Week High
- VALE $13.14
- ARGX $678.21
- Technical
- Relative Strength Index (RSI)
- VALE 49.34
- ARGX 36.21
- Support Level
- VALE $9.17
- ARGX $529.11
- Resistance Level
- VALE $9.43
- ARGX $658.93
- Average True Range (ATR)
- VALE 0.16
- ARGX 17.55
- MACD
- VALE 0.01
- ARGX -6.04
- Stochastic Oscillator
- VALE 30.00
- ARGX 15.82
About VALE VALE S.A.
Vale SA is a large global miner and the world's largest producer of iron ore and pellets. In recent years the company has sold noncore assets such as its fertilizer, coal, and steel operations to concentrate on iron ore, nickel, and copper. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets. The base metals division is much smaller, consisting of nickel mines and smelters along with copper mines producing copper in concentrate. Vale has agreed to sell a minority 13% stake in energy transition metals, its base metals business, which is expected to become effective in 2024, and which is likely the first step in separating base metals and iron ore.
About ARGX argenx SE
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.